Nanomedicine In Vivo Biomarkers
The Coronary artery disease is an entity with high prevalence worldwide. The treatment of patients in the acute phase of myocardial infarction and secondary prevention post-myocardial have made great strides in recent years, however, the mechanisms for primary prevention or early detection in high-risk patients has not been developed precisely. Scientific evidence suggests that the inflammatory process plays an essential role in all states of the atherogenesis, meaning that it involves not only the progression of coronary plaque but it appears to play a critical role in its rupture. Recently, it has been detected by histopathology, immunohistochemistry and noninvasive imaging techniques, various regulators of inflammation that may be related to the atherosclerotic plaque instability. Erosion and coronary plaque rupture occurs in early stages of acute coronary syndromes, therefore the early detection of potentially unstable plaques can prevent heart attacks.
Our goal is to identify inflammation markers on unstable plaques surface that can be used as indicators of the rupture risk. We will develop labeled biomarkers for vulnerable coronary atherosclerotic plaque rupture that can be detected with intravascular imaging devices.
Group manager Marina Brito